Printer Friendly

Mylan Inc markets first generic antifungal Vfend Tablets.

M2 EQUITYBITES-February 16, 2011-Mylan Inc markets first generic antifungal Vfend Tablets(C)2011 M2 COMMUNICATIONS

Specialist pharmaceutical company Mylan Inc (Nasdaq:MYL) revealed on Tuesday that it has launched Voriconazole Tablets, 50 mg and 200 mg, in the market.

Voriconazole Tablets have been launched by the company subsidiary, Mylan Pharmaceuticals Inc, under a previous settlement and license agreement with Pfizer.

Mylan stated that it was the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for Voriconazole Tablets and was awarded 180 days of marketing exclusivity.

The company said Voriconazole Tablets are the generic version of Pfizer's Vfend Tablets, a triazole antifungal agent.

According to IMS Health, Vfend Tablets recorded US sales of approximately USD186m for the 12 months ending 31 December 2010.

((Comments on this story may be sent to

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Feb 16, 2011
Previous Article:-Swedish PA Resources slips to loss in 2010 on higher costs, tax.
Next Article:-Swedish Orexo swings to net profit of SEK2.2m in Q4 2010.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters